INHALATIONAL ANESTHETICS Nitrous Oxide (N 2 O)

Similar documents
Pharmacokinetics. Inhalational Agents. Uptake and Distribution

INHALATION AGENTS 2013/05/28 1

Inhalation anesthesia. Somchai Wongpunkamol,MD Anes., CMU

ISPUB.COM. Review Of Currently Used Inhalation Anesthetics: Part II. O Wenker SIDE EFFECTS OF INHALED ANESTHETICS CARDIOVASCULAR SYSTEM

Volatile Anaesthetic Agents (Basic Principles)

General Anesthesia. Mohamed A. Yaseen

Inhalational Anesthesia. Munir Gharaibeh, MD, PhD, MHPE School of Medicine The University of Jordan February, 2018

ISPUB.COM. Review Of Currently Used Inhalation Anesthetics: Part I. O Wenker INTRODUCTION HISTORY

F Br F C C H. F Cl Halothane

Pharmacology of Inhalational Anaesthetics. John Myatt Correspondence

Inhalational Anaesthetic Agents

Pharmacology: Inhalation Anesthetics

General anesthesia. No single drug capable of achieving these effects both safely and effectively.

Pharmacology of Inhaled Anesthetics

Chapter 25. General Anesthetics

PCTH 400 Systematic Pharmacology

MANAGEMENT OF WASTE ANESTHESIA GAS NO DISCLOSURES

May 2013 Anesthetics SLOs Page 1 of 5

Asthma Management in ICU. by DrGary Au From KWH

General anesthetics. Dr. Shamil AL-Noaimy Lecturer of Pharmacology Dept. of Pharmacology College of Medicine

General Anesthetics. General Anesthesia Characteristics. Balanced Anesthesia. Types of General Anesthetics. Four Stages of Anesthesia

PCTH General Anaesthetics Nov 5 th 2013 (9:30-10:50) Location Woodward 6

Anesthesia Types in Rodents. Injectable or Inhalation Anesthesia? Why Anesthetize an Animal. Injectable Anesthetics - Disadvantages

Nothing to Disclose. Severe Pulmonary Hypertension

Frederic J., Gerges MD. Ghassan E. Kanazi MD., Sama, I. Jabbour-Khoury MD. Review article from Journal of clinical anesthesia 2006.

Cardiovascular Responses to Exercise

10/11/2015. Arif Alam, MD, FAAP Pediatric Critical Care Medicine Dept. Of Pediatrics CJW Chippenham Medical Center

Neurophysiology Lecture One : Neurophysiology and Evoked Potentials Lecture Two: Clinical Neuroanesthesia

Drug Profiles Professional Responder

Information Often Given to the Nurse at the Time of Admission to the Postanesthesia Care Unit

Medical APMLE. Podiatry and Medical.

Chapter 55. Changes in the Airway With COPD. Manifestations of Severe COPD. Drugs Used to Treat Obstructive Pulmonary Disorders

Marcel Perret-Gentil, DVM, MS University Veterinarian & Director Laboratory Animal Resources Center The University of Texas at San Antonio

General Anesthesia. My goal in general anesthesia is to stop all of these in the picture above (motor reflexes, pain and autonomic reflexes).

ANESTHETIZING DISEASED PATIENTS: URINARY; NEUROLOGICAL; TRAUMATIZED

COMPOSITION Each bottle contains the active ingredient, sevoflurane, only. No additive or stabilizer is present.

General Anesthetics Pharmacology

Anesthetic Techniques in Endoscopic Sinus and Skull Base Surgery

GENERAL ANAESTHESIA. Jozef Firment, MD PhD. Department of Anaesthesiology & Intensive Care Medicine Šafárik University Faculty of Medicine, Košice

RESPIRATORY PHARMACOLOGY - ASTHMA. Primary Exam Teaching - Westmead ED

Anesthesia Final Exam

Agonists: morphine, fentanyl Agonists-Antagonists: nalbuphine Antagonists: naloxone

Sevoflurane: Approaching the Ideal Inhalational Anesthetic A Pharmacologic, Pharmacoeconomic, and Clinical Review

R Adams Cowley Founder of the R Adams Cowley Shock Trauma Center and Maryland EMS System in Baltimore, Maryland.

Systemic Pharmacology Lecture 7: Neuropharmacology

General and Local Anesthetics TURNING POINT PHARM THURSDAY IMC606 Neuroscience Module

Fundamental Knowledge: List of topics relevant to PIC that will have been covered in membership examinations. They will not be repeated here.

Lecture Notes. Chapter 3: Asthma

Indications. Physical Properties of Nitrous Oxide. Nitrous Oxide/Oxygen Conscious Sedation in the Pediatric Patient. Steven Chussid, D.D.S.

Acid-base management during hypothermic CPB alpha-stat and ph-stat models of blood gas interpretation

ANESTHESIA EXAM (four week rotation)

CEREBRAL PHYSIOLOGY CEREBRAL PHYSIOLOGY REGULATION OF CBF REGULATION OF CBF REGULATION OF CBF. Cerebral Blood Flow (CBF)

Lecture Notes. Chapter 9: Smoke Inhalation Injury and Burns

OP01 [Mar96] With regards to pethidine s physical properties: A. It has an octanol coefficient of 10 B. It has a pka of 8.4

PRODUCT MONOGRAPH. Pr SEVOFLURANE. sevoflurane, USP % v/v sevoflurane (on anhydrous basis) Liquid for Inhalation. Inhalation Anesthetic

ULTANE (sevoflurane) volatile liquid for inhalation NOVAPLUS

7/21/2017. Learning Objectives. Current Cardiovascular Pharmacology. Epinephrine. Cardiotonic Agents. Epinephrine. Epinephrine. Arthur Jones, EdD, RRT

CEREBRAL EFFECTS OF SEVOFLURANE IN THE DOG COMPARISON WITH ISOFLURANE AND ENFLURANE

HOW LOW CAN YOU GO? HYPOTENSION AND THE ANESTHETIZED PATIENT.

SEVOFLURANE. Sevoflurane, USP Liquid for Inhalation. Volatile Liquid 99.97% w/w sevoflurane (on anhydrous basis)

Ideal Sedative Agent. Pharmacokinetics. Benzodiazepines. Pharmacodynamics 11/11/2013

Ideal Sedative Agent. Benzodiazepines 11/12/2013. Pharmacology of Benzodiazepines Used for Conscious Sedation in Dentistry.

Anesthesia and Mitochondrial Cytopathies Bruce H. Cohen, MD, John Shoffner, MD, Glenn DeBoer, MD United Mitochondrial Disease Foundation, 1998

Blood Brain Barrier (BBB)

Care of the Deteriorating Patient in Recovery NADIA TICEHURST : CLINICAL NURSE EDUCATOR PERI ANAESTHETICS BENDIGO HEALTH

DRUG CLASSES BETA-ADRENOCEPTOR ANTAGONISTS (BETA-BLOCKERS)

Malignant Hyperthermia: What the ICU Needs to Know

Fentanyl Citrate Injection, USP CII

PRODUCT MONOGRAPH. Sevoflurane volatile liquid ( % v/v sevoflurane on anhydrous basis) Inhalation Anesthetic

-Cardiogenic: shock state resulting from impairment or failure of myocardium

Blood pressure control Contin. Reflex Mechanisms. Dr. Hiwa Shafiq

Platelet aggregation inhibitor. Cardiac chest pain or suspected Myocardial Infarction.

CHAPTER 2 LITERATURE REVIEW. proceedings either. Anesthesia increases patient comfort, which can in turn

SAFETY DATA SHEET SECTION 1: PRODUCT IDENTIFICATION PRODUCT: Hand Sanitizer Product Label Name:

Weeks 1-3:Cardiovascular

The adrenergic drugs affect receptors that are stimulated by norepinephrine or epinephrine. Some adrenergic drugs act directly on the adrenergic

Pharmacokinetic Phase

Dr. Gavin Parker PINCHER CREEK AB 140

INTRODUCTION The effect of CPAP works on lung mechanics to improve oxygenation (PaO 2

Composition Each ml of Ventol solution for inhalation contains 5 mg Salbutamol (as sulphate).

CHAPTER 11. General and Local Anesthetics. Anesthetics. Anesthesia. Eliza Rivera-Mitu, RN, MSN NDEG 26 A

OOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOO

Pharmacology of anaesthetic agents II: inhalation anaesthetic agents

Chapter 18 Neuromuscular Blocking Agents Study Guide and Application Exercise

Control of Ventilation [2]

Drug Choices and Outcomes in Neuroanesthesia

10. Thick deposits of lipids on the walls of blood vessels, called, can lead to serious circulatory issues. A. aneurysm B. atherosclerosis C.

ISOFLURANE SAFETY GUIDELINES

MATERIAL SAFETY DATA SHEET MSDS No.: 008

Nitrous Oxide and the Inhalation Anesthetics

DBL NALOXONE HYDROCHLORIDE INJECTION USP

Optimal sedation and management of anxiety in patients undergoing endobronchial ultrasound (EBUS)

Name: Class: "Pharmacology NSAIDS (1) Lecture

Neurophysiology Lecture One : Neurophysiology and Evoked Potentials Lecture Two: Clinical Neuroanesthesia

Anesthesia For The Elderly. Yasser Sakawi, M.D. Associate Professor Anesthesiology Department

NEW ZEALAND DATA SHEET

Handling Common Problems & Pitfalls During. Oxygen desaturation in patients receiving mechanical ventilation ACUTE SEVERE RESPIRATORY FAILURE

Angina Pectoris Dr. Shariq Syed

BIPN100 F15 Human Physiol I (Kristan) Lecture 14 Cardiovascular control mechanisms p. 1

Pulmonary Pathophysiology

Transcription:

INHALATIONAL ANESTHETICS Nitrous Oxide (N 2 O) -low molecular weight, clear, odorless, inert, inorganic gas -non-flammable but does support combustion -gas at room temperature, kept as liquid under pressure -low blood solubility (B:G partition coefficient 0.47) "=> rapid induction -low tissue solubility (tissue gas solubility coefficient 1.22) "=> rapid emergence -oil:gas partition coefficient 1.4 -weak anesthetic (MAC 104%) most commonly used in conjunction with a volatile anesthetic or moderate dose narcotic technique -MAC awake approximately 60% -prominent analgesic effects -minimal skeletal muscle relaxation -may play a role in the development of PONV but studies remain inconclusive (E. Eger states that there is no difference in the occurrence of PONV in cases which used N 2 O 50% vs. those which used none) respiratory effects: -minimal at [ ] of 50% or less -does not increase PaCO 2 -produces little ventilatory depression -profoundly depresses the ventilatory response to arterial hypoxemia -*is the only inhalational anesthetic to increase pulmonary vascular resistance, especially in patients with preexisting pulmonary hypertension CV effects: -produces either no change or modest increases in BP, SVR and CO from activation of the SNS -depresses the carotid sinus -produces mild sympathetic stimulation as evidenced by: -increase in plasma catecholamines -mydriasis -increase in body temperature -diaphoresis -increase in RAP

-vasoconstriction of the pulmonary and systemic circulations, including cutaneous beds -causes profound circulatory depression in the presence of opioids as evidenced by: -decrease in BP, CO -increases LVEDP and SVR ***lt is possible that opioids inhibit the sympathomimetic effects of N 2 O thereby unmasking a cardiac depressant effect excretion: -eliminated primarily as an expired gas -approximately 0.004% undergoes reductive metabolism to nitrogen from activity of anaerobic bacteria in the Gl tract miscellaneous: -does not potentiate the effects of non-depolarizing muscle relaxants -does not trigger MH ***because it is 34X more soluble than nitrogen in the blood, it diffuses into air containing body cavities and can increase the pressure or expand the volume of gas in these cavities resulting in: -distention of the bowel -expansion or rupture of pulmonary cysts -expansion or rupture of the tympanic membrane in an occluded middle ear -pneumoencephalus -expansion of air emboli in the bloodstream -expansion of pneumothorax -expansion of cuffs of ETT or LMA -causes a negative Ames test but has been implicated in causing an increased incidence of SAB in OR and PACU personnel -irreversibly oxidizes the cobalt atom of vitamin B 12 thereby inactivating it and interfering with the synthesis of these enzymes: -methionine synthase (important in the formation of myelin) -thymidylate synthase (important in the formation of DMA) -may cause megaloblastic changes and agranulocytosis in bone marrow which is directly related to the interference of DMA synthesis-has a deleterious effect on hematopoiesis ***contraindicated for use in pregnancy, the immunosuppressed, and pts with pernicious anemia -overexposure may lead to peripheral neuropathies

isoflurane (Forane) F Ci F i i i F-C-C-0-C-H i i i F H F -a halogenated hydrocarbon (methyl ethyl ether); an isomer of enflurane -clear, non-flammable liquid at room temperature -pungent, ethereal odor -extremely stable not degraded by soda lime or light -vapor pressure 240 mm Hg -molecular weight 184 -since it is an isomer of enflurane, it exhibits similar pharmacologic properties -devoid of seizure activity, hepatic, or renal damage -intermediate blood solubility (B:G partition coefficient 1.4) -tissue gas solubility 110 -MAC 1.15% (intermediate potency) -MAC awake approximately 173 rd of MAC -oikgas solubility 91 respiratory effects: -produces significant respiratory depression (dose dependent) CV effects: -cardiac output may increase from SNS response to hypercapnia from hypoventilation -may possess some intrinsic sympathomimetic properties -*most potent vasodilator of the volatile agents; decreases SVR -causes coronary steal in steal-prone pts -does not sensitize the myocardium to catecholamines CNS effects: -same as the other volatiles with regard to CMRO 2) CBF, and ICP renal/hepatic effects: -least deleterious effect on both systems actually best of all the volatiles at preserving hepatic blood flow

muscular: -provides profound skeletal muscle relaxation greatest of all of the volatile agents -potentiates the effects of the NDMBs -relaxes uterine smooth muscle -triggers MH excretion: -primarily excreted unchanged as expired gas -undergoes minimal hepatic degradation (approximately 0.2%)

desflurane (Suprane) F F F I t i F-C-C-0-C-H i i i F H F -a fluorinated methyl ethyl ether structurally similar to isoflurane with substitution of a fluorine atom on the alpha ethyl carbon -vapor pressure 664 mm Hg must be vaporized through a heater -molecular weight 168 -stable in soda lime -pungent odor; may irritate airways especially at [ ] > than 1 MAC -MAC 4.58% to 6.3% (not extremely potent) -MAC awake approximately I/3" 1 of MAC -insoluble in blood (B:G coefficient 0.42) c >rapid induction/emergence expected -low oil:gas partition coefficient 18.7 -low tissue:gas partition coefficient (35); surrendered quickly as agent dissipates CV, respiratory, CMS, hepatic, renal, muscular effects: -thought to be similar in effects on all systems to isoflurane; may have a slightly greater effect in decreasing SVR -newer studies report that cardiac stimulation (i.e. tachycardia) is noted with rapid increases in [ ] -does not cause coronary steal in canine model; human studies pending -does not sensitize the myocardium to catecholamines -may provide cardiac protection in the face of ischemia -does not bronchodilate may actually cause bronchoconstriction and respiratory irritation (6% or greater) especially in smokers -may impair cerebral autoregulation at [ ] > 0.5 MAC -reports of greater incidence of PONV -recently reported to cause less post-operative delirium in the pedi population -**may cause CO toxicity if administered through desiccated soda lime metabolism: -undergoes minimal biotransformation in the liver (approximately 0.02%)

sevoflurane (Ultane) F l F - C - F F H-C-0-C-H F-C-F I F H -a fluorinated methyl ethyl ether -vapor pressure 160 mm Hg -molecular weight 200 -unstable in soda lime leads to formation of Compound A which is nephrotoxic (occurrence primarily in Baralyme) ***fresh gas flows of <2l/min not recommended -odor less pungent; well accepted for inhalation induction -may react with glass; H 2 O added as a preservative; unnecessary in plastic or aluminum containers -insoluble in blood (B:G coefficient 0.69) -tissue:gas solubility 99 -MAC 1.71 (intermediate potency) -MAC awake approximately l/3 rd of MAC -poor lipid solubility (oil:gas partition coefficient 55) CV effects: -similar effects as other volatiles, particularly desflurane -does not cause SNS stimulation with rapid increases in [ ] -does not cause coronary steal -does not sensitize the heart to catecholamines -mildly depresses myocardial contractility CNS effects: -preserves cerebral autoregulation at [ ] up to 1.5 MAC -increase in CBF parallels ICP -recent reports of seizure activity with high [ j in a non-epileptic pt respiratory effects: -depresses respiration like other volatiles -non-irritating to the airways; may reverse bronchospasm, status asthmaticus hepatic, muscular effects: -similar to those of desflurane -triggers MH metabolism: -deflourination exceeds that of enflurane; still only 1/3 rd of potential renal toxic dose -undergoes minimal hepatic degradation (2-3%)